Efficacy and Safety of Switching From Retrovir to Tenofovir or Abacavir in HIV-Infected Patients - Related Studies

Efficacy and Safety of Switching From Retrovir to Tenofovir or Abacavir in HIV-Infected Patients (SWAP)

This study is not yet open for participant recruitment.

Study NCT00647244. Last updated on March 28, 2008. Information provided by University of Aarhus

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		HIV Infections

2	Additional conditions recognized in this trial
		Acquired Immunodeficiency Syndrome
		Infection

3	More general conditions related to this trial
		Immune System Diseases
		Immunologic Deficiency Syndromes
		Lentivirus Infections
		Retroviridae Infections
		RNA Virus Infections
		Sexually Transmitted Diseases
		Sexually Transmitted Diseases, Viral
		Slow Virus Diseases
		Virus Diseases

4	Interventions listed in this trial
		Tenofovir disoproxil fumarate
		Abacavir

5	Additional drug interventions recognized in this trial
		Tenofovir
		Tenofovir disoproxil

6	More general drug interventions related to this trial
		Anti-HIV Agents
		Anti-Infective Agents
		Anti-Retroviral Agents
		Antiviral Agents
		Enzyme Inhibitors
		Molecular Mechanisms of Pharmacological Action
		Nucleic Acid Synthesis Inhibitors
		Pharmacologic Actions
		Reverse Transcriptase Inhibitors
		Therapeutic Uses

7	Sponsors listed in this trial
		Aarhus University Hospital